Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.
作者信息
Bloom Matthew D, Gibney Joseph M, Heldermon Coy D
机构信息
University of Florida Department of Medicine, Box 100278, 1600 SW Archer Road, Gainesville, Florida, 32610.
出版信息
Cancer Treat Commun. 2016;7:1-3. doi: 10.1016/j.ctrc.2016.02.006.
Abstract
摘要
相似文献
1
Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.拉帕替尼治疗晚期乳腺癌患者出现舌部色素沉着：一例报告
Cancer Treat Commun. 2016;7:1-3. doi: 10.1016/j.ctrc.2016.02.006.
2
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.拉帕替尼：一种小分子表皮生长因子受体和人表皮生长因子受体-2 酪氨酸激酶抑制剂，用于治疗乳腺癌。
Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029.
3
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.拉帕替尼：一种人表皮生长因子受体酪氨酸激酶的双重抑制剂。
Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008.
4
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.拉帕替尼在乳腺癌中的应用——HER1（表皮生长因子受体）、HER2、PTEN和PIK3CA基因的预测意义及拉帕替尼血药浓度评估
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):281-8. doi: 10.5507/bp.2010.043.
5
Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.拉帕替尼通过表皮生长因子受体/HuR 相互作用介导环氧化酶-2 的表达，增强三阴性乳腺癌细胞的侵袭性。
Mol Pharmacol. 2013 Apr;83(4):857-69. doi: 10.1124/mol.112.082743. Epub 2013 Jan 25.
6
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.拉帕替尼单药治疗晚期炎性乳腺癌中针对人表皮生长因子受体2（HER-2）反应的预测生物标志物谱的II期研究。
J Clin Oncol. 2008 Mar 1;26(7):1066-72. doi: 10.1200/JCO.2007.13.9949. Epub 2008 Jan 22.
7
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.曲妥珠单抗与 EGFR/HER-2 酪氨酸激酶抑制剂在 HER-2 阳性乳腺癌细胞中的协同作用。
Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5. Epub 2010 Mar 16.
8
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.HER-2基因扩增、HER-2和表皮生长因子受体的mRNA及蛋白表达，以及拉帕替尼在转移性乳腺癌女性患者中的疗效
Clin Cancer Res. 2008 Dec 1;14(23):7861-70. doi: 10.1158/1078-0432.CCR-08-1056.
9
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.拉帕替尼：一种用于癌症治疗的新型表皮生长因子受体/人表皮生长因子受体2酪氨酸激酶抑制剂
Drugs Today (Barc). 2006 Jul;42(7):441-53. doi: 10.1358/dot.2006.42.7.985637.
10
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.拉帕替尼联合卡培他滨与单用卡培他滨治疗曲妥珠单抗治疗后进展的晚期乳腺癌女性患者的III期随机对照试验：疗效更新及生物标志物分析
Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.
引用本文的文献
1
Drug-induced Tongue Disorders: A Comprehensive Literature Review.药物性舌部疾病：一篇综合文献综述
Curr Drug Saf. 2025;20(2):148-213. doi: 10.2174/0115748863299971240513061630.
2
Pigmented Fungiform Papillae (PFP) of the Tongue: A Systematic Review of Current Aetiopathogenesis and Pathophysiology.舌部色素性菌状乳头（PFP）：当前病因发病机制和病理生理学的系统评价
Pathophysiology. 2022 Sep 9;29(3):555-569. doi: 10.3390/pathophysiology29030043.
本文引用的文献
1
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).拉帕替尼联合曲妥珠单抗治疗人表皮生长因子受体2阳性转移性乳腺癌患者的II期研究：早期[18F]氟脱氧葡萄糖正电子发射断层扫描成像的临床结果及预测价值（TBCRC 003）
J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13.
2
Mucosal hyperpigmentation from prophylactic minocycline for EGFR inhibitor.用于表皮生长因子受体抑制剂的预防性米诺环素引起的黏膜色素沉着。
J Eur Acad Dermatol Venereol. 2016 Apr;30(4):690-2. doi: 10.1111/jdv.12978. Epub 2015 Jan 28.
3
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.拉帕替尼引起的皮疹、腹泻和肝毒性的模式及其与年龄和新辅助治疗反应的关系：来自 NeoALTTO 试验的分析。
J Clin Oncol. 2013 Dec 20;31(36):4504-11. doi: 10.1200/JCO.2013.50.9448. Epub 2013 Nov 18.
4
Chemotherapy-associated tongue hyperpigmentation and blue lunula.化疗相关的舌部色素沉着及蓝色甲半月征
J Drugs Dermatol. 2013 Feb;12(2):223-6.
5
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.曲妥珠单抗联合拉帕替尼治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者的总生存获益：EGF104900 研究的最终结果。
J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.
6
Mucosal pigmentation caused by imatinib: report of three cases.伊马替尼引起的黏膜色素沉着：三例报告
Head Neck Pathol. 2012 Jun;6(2):290-5. doi: 10.1007/s12105-011-0325-4. Epub 2011 Dec 31.
7
Black hairy tongue associated with erlotinib treatment in a patient with advanced lung cancer.一名晚期肺癌患者使用厄洛替尼治疗后出现黑毛舌。
Ann Dermatol. 2011 Nov;23(4):526-8. doi: 10.5021/ad.2011.23.4.526. Epub 2011 Nov 3.
8
Oral complications of targeted cancer therapies: a narrative literature review.靶向癌症治疗的口腔并发症：一篇叙述性文献综述。
Oral Oncol. 2011 Jun;47(6):441-8. doi: 10.1016/j.oraloncology.2011.03.028. Epub 2011 Apr 22.
9
An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?卡培他滨致皮肤色素沉着异常 1 例：皮肤色素沉着是手足综合征的一部分，还是一个独立的实体？
Indian J Pharmacol. 2010 Oct;42(5):326-8. doi: 10.4103/0253-7613.70401.
10
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.表皮生长因子受体抑制剂相关皮肤不良反应的管理：德国专家小组对一线治疗医师的建议。
J Dtsch Dermatol Ges. 2011 Mar;9(3):195-203. doi: 10.1111/j.1610-0387.2010.07561.x. Epub 2010 Nov 8.
Zotero 插件